Fibroblast growth factor 4

FGF receptors (FGFRs) are involved in the pathogenesis

fallback-image

Spike Protein Luciferase

Human Centriole and Centrosome Antibody IgG ELISA Kit

MBS039049-10x96StripWells 10x96-Strip-Wells
EUR 6725

Human IgG antibody Laboratories manufactures the spike protein luciferase reagents distributed by Genprice. The Spike Protein Luciferase reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Spike products are available in stock. Specificity: Spike Category: Protein Group: Luciferase

Human True insulin ELISA kit

1 plate of 96 wells
EUR 822
Description: A competitive ELISA for quantitative measurement of Human True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human True insulin ELISA kit

96T
EUR 700
Description: ELISA

Human True Insulin ELISA Kit

10x96-Strip-Wells
EUR 6725

Human True Insulin ELISA Kit

48-Strip-Wells
EUR 550

Human True Insulin ELISA Kit

5x96-Strip-Wells
EUR 3420

Human True Insulin ELISA Kit

96-Strip-Wells
EUR 765

Human True Insulin GENLISA ELISA

1 x 96 wells
EUR 286

Luciferase information

Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78644-2 500 µl x 2
EUR 3995
Description: The Spike protein of BA.4 and BA.5 variants of SARS-CoV-2 have identical mutations. In this datasheet, the spike protein of BA.4 and BA.5 are referred to as BA.4/5._x000D_The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.4/5 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.4/5, Omicron Variant:_x000D_Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-100 µl

78641-1 100 µl
EUR 795
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility.As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in BA.1.1 Omicron Variant:A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F

Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-500 µl x 2

78641-2 500 µl x 2
EUR 3995
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility._x000D_As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells._x000D_Spike Mutations in BA.1.1 Omicron Variant:_x000D_A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F

Luciferase Protein

abx073317-20kDa1g 20 kDa; 1 g
EUR 225

Luciferase Protein

abx073317-2kDa1g 2 kDa; 1 g
EUR 3550

Luciferase Protein

abx073317-5kDa1g 5 kDa; 1 g
EUR 325

Luciferase protein (His tag)

80R-1462 100 ug
EUR 307
Description: Purified recombinant firefly Luciferase protein

firefly Luciferase Recombinant Protein

PROTA3KBZ5 20ug
EUR 250
Description: Firefly Luciferase Recombinant Protein expressed in E. coli with His-tag. Sequence domain: 1-550aa. Application(s): SDS-PAGE.

COVID-19 S Protein / (Luciferase)-(6His) VLP

VLP002 1x108 VP/ml x 200ul
EUR 455
Description: COVID-19 Spike protein (S) Virus Like Particle, packaged with firefly luciferase genomic material. Particles were concentrated and provided in PBS solution

OPPA02425-5UG - Luciferase Firefly Protein

OPPA02425-5UG 5ug
EUR 70

renilla reniformis Luciferase Recombinant Protein

PROTP27652 10ug
EUR 241
Description: renilla reniformis Luciferase Recombinant Protein expressed in E. coli with His-tag. Sequence domain: 1-311aa. Application(s): SDS-PAGE, Enzyme Activity. Endotoxin: < 1 EU per 1ug of protein (determined by LAL method).

Luciferase Luciferin 4-Monooxygenase Firefly Recombinant Protein

PROTP08659 Regular: 20ug
EUR 380.4
Description: Luciferase produced in E.Coli is a single, non-glycosylated polypeptide chain containing 571 amino acids (1-550 a.a.) and having a molecular mass of 62.9kDa.;Luciferase is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Recombinant other Luciferase Firefly Protein, His, E.coli-1ug

QP10776-1ug 1ug
EUR 186

Recombinant other Luciferase Firefly Protein, His, E.coli-5ug

QP10776-5ug 5ug
EUR 241.2

Recombinant other Luciferase Firefly Protein, His, E.coli-1mg

QP12597-1mg 1mg
EUR 3308.4

Recombinant Photinus pyralis Luciferase protein, N-His Tag

MBS157146-005mg 0.05mg
EUR 320

Recombinant Photinus pyralis Luciferase protein, N-His Tag

MBS157146-01mg 0.1mg
EUR 410

Recent Posts

Tags

December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Categories